公开(公告)号：US20110177084A1

公开(公告)日：2011-07-21

申请号：US13054556

申请日：2009-07-17

申请人： Takashi Saito ,  Sho Yamasaki

发明人： Takashi Saito ,  Sho Yamasaki

IPC分类号： A61K39/395 ,  A61K38/08 ,  A61K31/7088 ,  A61K31/713 ,  C12Q1/34 ,  C12Q1/02 ,  C12Q1/68 ,  A61P29/00

CPC分类号： G01N33/564 ,  A61K31/7105 ,  G01N33/57407 ,  G01N2333/7056 ,  G01N2500/00 ,  G01N2800/065 ,  G01N2800/10 ,  G01N2800/102 ,  G01N2800/20 ,  G01N2800/202 ,  G01N2800/205 ,  G01N2800/22 ,  G01N2800/245 ,  G01N2800/26 ,  G01N2800/325 ,  G01N2800/328 ,  G01N2800/329

摘要： Provided are a novel means for regulating inflammatory reactions by regulating the signaling in inflammatory responses caused by non-homeostatic cell death, specifically an anti-inflammatory agent comprising a substance that inhibits the expression of Mincle or the interaction of Mincle and SAP130 or FcRγ, a screening method for a substance that regulates inflammatory reactions, comprising contacting Mincle or a fragment containing an extracellular region thereof and SAP130 in the presence and absence of a test substance, and comparing the degrees of the interaction of Mincle or the fragment thereof and SAP130 under the two conditions, a method of detecting non-homeostatic cell death, comprising measuring the amount of SAP130 in a sample collected from a subject animal, and the like.

摘要翻译： 提供了一种通过调节由非稳态细胞死亡引起的炎性反应中的信号传导来调节炎症反应的新颖手段，具体地，包括抑制Mincle表达的物质或Mincle和SAP130或FcRγ的相互作用的抗炎药 包括调节炎症反应的物质的筛选方法，包括在存在和不存在测试物质的情况下接触Mincle或其含有细胞外区域的片段和SAP130，并将Mincle或其片段与SAP130的相互作用程度与 两个条件，检测非稳态细胞死亡的方法，包括测量从受试动物收集的样品中的SAP130的量等。

公开(公告)号：US20090186370A1

公开(公告)日：2009-07-23

申请号：US12355384

申请日：2009-01-16

申请人： Matthew F. Ogle ,  Jason C. Isenburg

发明人： Matthew F. Ogle ,  Jason C. Isenburg

IPC分类号： C12Q1/37 ,  G01N33/00 ,  C12Q1/02

CPC分类号： G01N33/6887 ,  G01N2333/78 ,  G01N2333/96494 ,  G01N2333/9723 ,  G01N2333/9726 ,  G01N2800/329 ,  Y10T436/173845

摘要： Biomarkers for diagnosis and monitoring of vascular aneurysms are described in the context of the use of assays to measure a plurality of these biomarkers. Tissue degeneration, particularly elastin and/or collagen degradation, can be monitored within patient blood (serum) and/or urine to diagnose the presence, the progression, or the likelihood of rupture of aneurismal disease. Additionally, enzymes responsible for this degradation and other biomarkers responsible for the activation or inhibition of these enzymes can be monitored additionally or alternatively. Prompt diagnosis can provide the opportunity for intervention and potentially increase the health of patients by tempering the development of debilitating and life-threatening vascular aneurysms.

摘要翻译： 用于诊断和监测血管动脉瘤的生物标志物在使用测定来测量多个这些生物标志物的背景下进行了描述。 可以在患者血液（血清）和/或尿液内监测组织变性，特别是弹性蛋白和/或胶原降解，以诊断动脉瘤疾病破裂的存在，进展或可能性。 此外，负责这种降解的酶和负责这些酶的活化或抑制的其他生物标志物可以被附加地或替代地监测。 快速诊断可以提供干预的机会，并通过回火衰老和危及生命的血管动脉瘤的发展来增加患者的健康。

公开(公告)号：US20090093005A1

公开(公告)日：2009-04-09

申请号：US12245322

申请日：2008-10-03

申请人： David M. Smalley ,  Nancy L. Harthun ,  Klaus F. Ley ,  Ian J. Sarembock ,  Kristina Little

发明人： David M. Smalley ,  Nancy L. Harthun ,  Klaus F. Ley ,  Ian J. Sarembock ,  Kristina Little

IPC分类号： G01N33/53 ,  G01N33/00 ,  C12Q1/00 ,  C12Q1/32 ,  C12Q1/48 ,  C12Q1/28 ,  G01N33/566

CPC分类号： G01N33/6893 ,  G01N2800/329

摘要： The present invention encompasses compositions and methods useful for diagnosing subjects with abdominal aortic aneurysms. The invention relates to the use of protein biomarkers whose levels are different in subjects with abdominal aortic aneurysms relative to normal subjects.

摘要翻译： 本发明包括用于诊断患有腹主动脉瘤的受试者的组合物和方法。 本发明涉及相对于正常受试者，腹主动脉瘤受试者的水平不同的蛋白质生物标志物的使用。

公开(公告)号：US20090029868A1

公开(公告)日：2009-01-29

申请号：US11981143

申请日：2007-10-30

申请人： Yulei Wang ,  Catalin Barbacioru ,  Raymond R. Samaha ,  John A. Elefteriades

发明人： Yulei Wang ,  Catalin Barbacioru ,  Raymond R. Samaha ,  John A. Elefteriades

IPC分类号： C40B30/04 ,  C12Q1/68

CPC分类号： C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N2800/329

摘要： We hypothesized that gene expression patterns in peripheral blood cells may correlate with TAA disease status, and carried out a comprehensive gene expression survey on peripheral blood cells obtained from TAA patients and normal individuals. A distinct gene expression profile in peripheral blood cells can classify TAA patients from normal individuals. The genes provided by the present teachings define a set of diagnostic markers, thus providing a blood-based gene expression test to facilitate early detection of TAA disease. Methods of distinguishing ascending from descending TAA are also provided, as are methods of distinguishing familial from sporadic TAA.

摘要翻译： 我们假设外周血细胞中的基因表达模式可能与TAA疾病状态相关，并对从TAA患者和正常个体获得的外周血细胞进行综合基因表达调查。 外周血细胞中不同的基因表达谱可以分类来自正常个体的TAA患者。 本教导提供的基因定义了一组诊断标记，从而提供了一种基于血液的基因表达测试，以促进TAA疾病的早期检测。 还提供了区分上升TAA的方法，以及区分家族与散发性TAA的方法。

公开(公告)号：US20080274453A1

公开(公告)日：2008-11-06

申请号：US11522297

申请日：2006-09-14

申请人： Gregory S. Hageman

发明人： Gregory S. Hageman

IPC分类号： C12Q1/68 ,  G01N33/53

CPC分类号： G01N33/6893 ,  G01N2800/164 ,  G01N2800/329

摘要： The invention relates to diagnostics and therapeutics and animal models for macular degeneration, specifically as they relate to the association described herein between macular degeneration and arterial wall disruptive disorders. In one embodiment, the invention provides kits and methods for diagnosing macular degeneration comprising identifying a marker for an arterial wall disruptive disorder, including an aneurysm. In one embodiment, the invention provides therapeutics for treating macular degeneration comprising delivering to a subject an agent useful for treating an arterial wall disruptive disorder, including an aneurysm.

摘要翻译： 本发明涉及用于黄斑变性的诊断和治疗学和动物模型，具体地说它们涉及黄斑变性与动脉壁破坏性疾病之间所述的关联。 在一个实施方案中，本发明提供用于诊断黄斑变性的试剂盒和方法，其包括鉴定包括动脉瘤的动脉壁破坏性病症的标志物。 在一个实施方案中，本发明提供治疗黄斑变性的治疗剂，其包括将可用于治疗动脉壁破坏性病症（包括动脉瘤）的药剂递送给受试者。

公开(公告)号：US6048704A

公开(公告)日：2000-04-11

申请号：US812586

申请日：1997-03-07

申请人： Martin David Tilson

发明人： Martin David Tilson

IPC分类号： A61K38/00 ,  C07K14/47 ,  C07K16/18 ,  G01N33/68 ,  G01N33/53 ,  C07H21/04 ,  G01N33/566

CPC分类号： G01N33/6893 ,  C07K14/4713 ,  C07K16/18 ,  A61K38/00 ,  G01N2800/329

摘要： This invention provides an isolated protein of approximately 40 kDa which is purified from human aortic tissue and immunoreactive with AAA-associated immunoglobulin. Also provided are a method of diagnosing AAA disease in a subject using said isolated protein and a pharmaceutical composition comprising said isolated protein. A method of alleviating AAA disease in a subject comprising administering said pharmaceutical composition comprising the isolated protein is also provided. The subject invention also provides a recombinantly produced human aortic protein which is immunoreactive with AAA-associated immunoglobulin. Also provided are a method of diagnosing AAA disease in a subject using said recombinantly produced protein and a pharmaceutical composition comprising said recombinantly produced protein. A method of alleviating AAA disease in a subject comprising administering said pharmaceutical composition comprising the recombinantly produced protein is also provided.